Study characteristics. by Maria-Sophie Brueckle (13816408)

“…</p><p>Results</p><p>Twenty-three RCTs (mean dosage 5mg to 300mg amitriptyline/day) and 4217 patients (mean age 40.3 years) were included. …”

Forest plots of primary outcomes. by Maria-Sophie Brueckle (13816408)

“…</p><p>Results</p><p>Twenty-three RCTs (mean dosage 5mg to 300mg amitriptyline/day) and 4217 patients (mean age 40.3 years) were included. …”

FACIT-Fatigue score normalization at baseline and after 16 weeks of pegcetacoplan treatment are shown for patients with PNH and mild/moderate anemia (hemoglobin ≥10.0 g/dL) in the... by Jens Panse (350046)

Fig 2 - by Jens Panse (350046)

Effects of melatonin on the TGF-β1/Smad pathway and EMT in a PS/LPS-induced bladder fibrosis model in rats. by Yang Zhang (30734)

Fig 1 - by Jens Panse (350046)

Fig 5 - by Jens Panse (350046)

Fig 3 - by Jens Panse (350046)

Decreased pMHC avidity and CD8β-independence for functional avidity of D^bNPN3A-primed T cells for D^bNP₃₆₆. by Sophie A. Valkenburg (176257)

Characteristics of JIA patients. by Yasmine Makhlouf (17409866)

“…Twelve studies published between 2003 and 2018 were analyzed, encompassing 1513 patients with a mean age of 11.4 years. Tumor necrosis factor alpha inhibitors were the predominant biologic agents used (75.8%), with a mean follow-up duration of 2 years post-biologic therapy initiation. …”

List of excluded articles. by Yasmine Makhlouf (17409866)

“…Twelve studies published between 2003 and 2018 were analyzed, encompassing 1513 patients with a mean age of 11.4 years. Tumor necrosis factor alpha inhibitors were the predominant biologic agents used (75.8%), with a mean follow-up duration of 2 years post-biologic therapy initiation. …”

<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates by Yejin Kim (740789)

“…Data are presented as mean ± standard error of the mean (SEM). (G) Reduction in liver fluorescence intensity in zebrafish embryos following slc2a2 morpholino (MO) injection. …”

Kaplan-Meier survival curve in patients using HFNC according to WOB at 12-24 hours. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to iROX. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to age. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to hypertension. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to PaO2/FiO2. by Edwin Aguirre-Milachay (15453672)

Characteristics of COVID-19 patients using high-flow nasal cannula according to mortality. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to IMV. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to WOB at admission. by Edwin Aguirre-Milachay (15453672)